Background: As teens with T1D become increasingly independent in self-care, adherence and glycemic control deteriorate. Teens need innovative ways to improve self-care and protect against glycemic decline. We evaluated a text messaging intervention in teens with T1D and assessed factors associated with text responsiveness and glycemic benefit over 18 months.

Methods: Teens with T1D (N=147), ages 13-17 years, received 2-way text reminders at self-selected times to check BG levels and reply by text with BG results. Teens received increasing numbers of text reminders, beginning with 1 and increasing to a maximum of 4/day.

Results: At baseline, teens (48% male, 78% white, 63% pump-treated) had mean±SD age 14.9±1.3 years, T1D duration 7.1±3.9 years, and A1c 8.5±1.1%. The mean proportion of days with 1+ BG response declined over time (months 0-6: 60±26% of days, months 6-12: 53±32%, months 12-18: 43±33%). Over the 18 month study, 50% of teens responded with 1+ BG result on ≥50% of days (“High Responders”). High Responders compared with “Low Responders” (<50% of days with 1+ BG response) were similar regarding age, T1D duration, and sex distribution but High Responders had lower baseline A1c (8.2±1.0 vs. 8.7±1.1%, p=.005) and higher daily BGM frequency (5.2±2.3 vs. 4.3±1.6, p=.01). Regression analysis controlling for baseline A1c revealed no significant change in A1c from baseline to 18 months in High Responders (p=.42) compared with a significant A1c increase in Low Responders (+0.3%, p=.009). In teens with baseline A1c ≥8%, High Responders (n=39) were 2.6 (95% CI 1.03, 6.6) times more likely than Low Responders (n=52) to improve A1c by ≥0.5% from baseline to 18 months (p=.04).

Conclusions: Responding to text reminders on ≥50% of days over 18 months provided clinically significant glycemic benefit to teens with T1D, especially in those with high baseline A1c. There remains a need to tailor interventions for teens over time to maintain their engagement and optimize improvements.


D.E. McGill: None. L. Volkening: None. D.A. Butler: None. W. Levy: None. R.M. Wasserman: None. B. Anderson: Advisory Panel; Self; Sanofi-Aventis. L.M. Laffel: Consultant; Self; Eli Lilly and Company, Novo Nordisk Inc., Sanofi US, MannKind Corporation, Roche Diagnostics Corporation, Dexcom, Inc., Insulet Corporation, AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Johnson & Johnson Diabetes Institute, LLC..

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at